Brain Penetrable Inhibitors of Ceramide Galactosyltransferase for the Treatment of Lysosomal Storage Disorders.

Abstract

Metachromatic leukodystrophy (MLD) is a rare, genetic lysosomal storage disorder caused by the deficiency of arylsulfatase A enzyme, which results in the accumulation of sulfatide in the lysosomes of the tissues of central and peripheral nervous systems, leading to progressive demyelination and neurodegeneration. Currently there is no cure for this disease, and the only approved therapy, hematopoietic stem cell transplant, has limitations. We proposed substrate reduction therapy (SRT) as a novel approach to treat this disease, by inhibiting ceramide galactosyltransferase enzyme (UGT8). This resulted in the identification of a thienopyridine scaffold as a starting point to initiate medicinal chemistry. Further optimization of hit compound 1 resulted in the identification of brain penetrable, orally bioavailable compound 19, which showed efficacy in the in vivo pharmacodynamic models, indicating the potential to treat MLD with UGT8 inhibitors.

• Authors: Sukanthini Thurairatnam, Sungtaek Lim, Robert H Barker Jr, Yong Mi Choi-Sledeski, Bradford H Hirth, John Jiang, John E Macor, Elina Makino, Sachin Maniar, Kwon Musick, James R Pribish, Mark Munson
• Journal: ACS medicinal chemistry letters (ACS Med Chem Lett) Vol. 11 Issue 10 Pg. 2010-2016 (Oct 08 2020) ISSN: 1948-5875 [Print] United States
• PMID: 33062186 (Publication Type: Journal Article)